A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Sponsor
Alnylam Pharmaceuticals
Study ID
NCT06423352
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Mild to Moderate Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Zilebesiran — DRUG
    Zilebesiran administered by subcutaneous (SC) injection
  • Placebo — DRUG
    Placebo administered by SC injection

Study Details

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.

Key Dates

Start date
Jun 5, 2024
Status verified
Apr 2026
Primary completion
Jul 17, 2025
Completion
Jul 17, 2025

Study Design

Enrollment
36 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Zilebesiran
    Participants will be administered a single dose of zilebesiran.
  • Placebo Comparator: Placebo
    Participants will be administered a single dose of placebo.

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) [ Time Frame: Up to 12 months ]

Related coverage on Hipa.ai

Related Studies